Skip to main content

Targeting treatment-induced neuroendocrine prostate cancer

Project description

Novel therapeutic target against prostate cancer

Current treatment options for prostate cancer include the use of androgen deprivation therapies to block tumour growth. However, the tumours often become castration-resistant. Approximately 25 % of the prostate cancer patients with castration-resistant disease treated with antiandrogens develop a form of prostate cancer that is completely independent of androgen receptor signalling, which promotes tumour growth. Analyses of the pathology and genomics of these patient tumours have identified that the tumour cells adapt cancer stem cell and neuronal cell characteristics. The EU-funded TARNEPC project aims to characterise a novel therapeutic target against aggressive treatment-resistant neuroendocrine prostate cancer.

Call for proposal

H2020-MSCA-IF-2019
See other projects for this call

Coordinator

ITA-SUOMEN YLIOPISTO
Address
Yliopistonranta 1 E
70211 Kuopio
Finland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 202 680,96